Dr. Bishal Gyawali
Common Sense Oncology believes that the design, analysis, and reporting of cancer clinical trials should always be aligned with the outcomes that matter most, and help ensure that new treatments deliver meaningful benefits for patients.
ASCO 2026 delivered a compelling mix of breakthrough science, practice-changing insights, and important reality checks, underscoring both the progress and the complexity of modern oncology. Of the many trials presented, five major trials have earned a dedicated special mention: RASolute 302, PUMP trial, CROWN study, Keynote 522, and OPTIMA.
Among the standout studies was the RASolute 302 trial, which may mark a turning point in metastatic pancreatic cancer—a disease that has long resisted meaningful advances. The KRAS inhibitor daraxonrasib nearly doubled overall survival while also improving quality of life. This rare alignment of efficacy and patient-centered outcomes signals a genuine advance and sets a new benchmark for care in this space. The only question that remains is if crossover was implemented, which would allow participants to switch between the control and treatment arms. However, the median survival for patients with this poor-prognosis disease even in daraxonrasib arm remained 13 months, signifying a lot of work still needs to be done.
Subsequent to the RASolute trial, the PUMP trial provided a sobering but equally important message: hepatic artery infusion pumps, despite their complexity and widespread use in some centers, failed to improve either progression-free or overall survival following colorectal liver metastasis surgery. These findings strongly challenge the continued use of a burdensome intervention without clear benefit, highlighting the importance of rigorously testing even well-established practices.
Long-term data also took center stage, particularly with the 7-year update of the CROWN trial in ALK-positive lung cancer. Lorlatinib demonstrated a striking progression-free survival rate of 55% compared to just 3% with crizotinib, with median PFS still unreached after seven years. Such durability is remarkable in a historically aggressive disease and reinforces the transformative potential of targeted therapies. Importantly, the study also suggested that dose reductions did not compromise efficacy, opening the door to strategies that could reduce toxicity and financial burden without sacrificing benefit.
In breast cancer, the KEYNOTE-522 trial provided definitive evidence that meaningful survival gains are achievable in curative settings, with an 8% absolute improvement in 7-year overall survival. At a time when marginal benefits are often debated, this magnitude of improvement stands out as both clinically significant and practice-affirming.
Equally impactful was the OPTIMA trial, which addressed a critical question in early breast cancer: can some patients safely avoid chemotherapy? The study showed that endocrine therapy alone was non-inferior to chemo-endocrine therapy in selected patients, even among those with traditionally higher-risk features. This represents a major step forward in personalizing treatment, potentially allowing many patients to avoid the toxicity of chemotherapy without compromising outcomes.
At ASCO 2026, real advances were made that require both enthusiasm and critical appraisal. The takeaways from these five trials include breakthrough therapies, long-term disease control, smarter care, and the need to abandon ineffective practices when strong evidence calls for it. Distinguishing meaningful progress from incremental or unsupported interventions remains essential to delivering the best outcomes for patients.